Data related to ZYTIGA™ (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The studies were sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc.
"We are pleased that these data have been selected for presentation at the 2011 ASCO Annual Meeting," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Ortho Biotech Oncology Research & Development, unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "We are committed to advancing scientific dialogue and understanding around our clinical studies in areas such as metastatic castration-resistant prostate cancer."
Ortho Biotech Oncology Research & Development